4.0 Article

Incorporating DNA barcodes into a multi-year inventory of the fishes of the hyperdiverse Lower Congo River, with a multi-gene performance assessment of the genus Labeo as a case study

期刊

MITOCHONDRIAL DNA
卷 22, 期 -, 页码 52-70

出版社

TAYLOR & FRANCIS LTD
DOI: 10.3109/19401736.2010.537748

关键词

Africa; fish; DNA barcoding; Congo; cytochrome c oxidase subunit I; RAG1

资金

  1. National Science Foundation (DEB ) [0542540]
  2. Axelrod Curatorship at AMNH
  3. Columbia University's Department of Ecology, Evolution, and Environmental Biology
  4. NSF
  5. AMNH
  6. Genome Canada via the Ontario Genomics Institute
  7. Natural Sciences and Engineering Research Council of Canada
  8. Direct For Biological Sciences
  9. Division Of Environmental Biology [0542540] Funding Source: National Science Foundation

向作者/读者索取更多资源

Background and aims: Here we describe preliminary efforts to integrate DNA barcoding into an ongoing inventory of the Lower Congo River (LCR) ichthyofauna. The 350 km stretch of the LCR from Pool Malebo to Boma includes the world's largest river rapids. The LCR ichthyofauna is hyperdiverse and rich in endemism due to high habitat heterogeneity, numerous dispersal barriers, and its downstream location in the basin. Materials and methods: We have documented 328 species from the LCR, 25% of which are thought to be endemic. In addition to detailing progress made to generate a reference sequence library of DNA barcodes for these fishes, we ask how DNA can be used at the current stage of the Fish Barcode of Life initiative, as a work in progress currently of limited utility to a wide audience. Two possibilities that we explore are the potential for DNA barcodes to generate discrete diagnostic characters for species, and to help resolve problematic taxa lacking clear morphologically diagnostic characters such as many species of the cyprinid genus Labeo, which we use as a case study. Results: Our molecular analysis helped to clarify the validity of some species that were the subject of historical debate, and we were able to construct a molecular key for all monophyletic and morphologically recognizable species. Several species sampled from across the Congo Basin and widely distributed throughout Central and West Africa were recovered as paraphyletic based on our molecular data. Conclusion: Our study underscores the importance of generating reference barcodes for specimens collected from, or in close proximity to, type localities, particularly where species are poorly understood taxonomically and the extent of their geographical distributions have yet to be established.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Chemistry, Medicinal

Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity

Ellen Watts, David Heidenreich, Elizabeth Tucker, Monika Raab, Klaus Strebhardt, Louis Chesler, Stefan Knapp, Benjamin Bellenie, Swen Hoelder

JOURNAL OF MEDICINAL CHEMISTRY (2019)

Article Oncology

Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability

Monika Raab, Mourad Sanhaji, Shengtao Zhou, Franz Roedel, Ahmed El-Balat, Sven Becker, Klaus Strebhardt

NEOPLASIA (2019)

Article Oncology

Boosting the apoptotic response of high-grade serous ovarian cancers withCCNE1amplification to paclitaxelin vitroby targeting APC/C and the pro-survival protein MCL-1

Monika Raab, Nene F. Kobayashi, Sven Becker, Elisabeth Kurunci-Csacsko, Andrea Kraemer, Klaus Strebhardt, Mourad Sanhaji

INTERNATIONAL JOURNAL OF CANCER (2020)

Article Multidisciplinary Sciences

Immune adaptor SKAP1 acts a scaffold for Polo-like kinase 1 (PLK1) for the optimal cell cycling of T-cells

Monika Raab, Klaus Strebhardt, Christopher E. Rudd

SCIENTIFIC REPORTS (2019)

Article Oncology

Association of Polo-Like Kinase 3 and PhosphoT273 Caspase 8 Levels With Disease-Related Outcomes Among Cervical Squamous Cell Carcinoma Patients Treated With Chemoradiation and Brachytherapy

Max Fleischmann, Daniel Martin, Samuel Pena-Llopis, Julius Oppermann, Jens von der Gruen, Markus Diefenhardt, Georgios Chatzikonstantinou, Emmanouil Fokas, Claus Roedel, Klaus Strebhardt, Sven Becker, Franz Roedel, Nikolaos Tselis

FRONTIERS IN ONCOLOGY (2019)

Article Multidisciplinary Sciences

GTPase-activating protein Rasal1 associates with ZAP-70 of the TCR and negatively regulates T-cell tumor immunity

Youg Raj Thaker, Monika Raab, Klaus Strebhardt, Christopher E. Rudd

NATURE COMMUNICATIONS (2019)

Review Biochemistry & Molecular Biology

Caspase-8: The double-edged sword

Ranadip Mandal, Joan Compte Barron, Izabela Kostova, Sven Becker, Klaus Strebhardt

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2020)

Review Oncology

The role of caspase-8 in the tumor microenvironment of ovarian cancer

Izabela Kostova, Ranadip Mandal, Sven Becker, Klaus Strebhardt

Summary: Caspase-8, a key regulator in multiple signaling pathways, not only controls cell cycle and behavior but also immune response and cytokine production within the tumor microenvironment. Dysregulated expression of caspase-8 in ovarian cancer influences tumor aggressiveness and immune resistance, highlighting its potential as a therapeutic target for developing new treatment strategies against the complex tumor microenvironment.

CANCER AND METASTASIS REVIEWS (2021)

Review Cell Biology

Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer

Monika Kressin, Daniela Fietz, Sven Becker, Klaus Strebhardt

Summary: Polo-like kinases (PLKs) are a group of highly conserved serine/threonine kinases that play crucial roles in tumorigenesis, particularly with the overexpression of PLK1 being associated with poor prognosis in different cancers. Current research is focusing on investigating the multiple functions of PLKs and their potential as cancer targets, with a specific emphasis on PLK1 and PLK4 inhibition in various cancer trials.
Article Oncology

The Small-Molecule Inhibitor MRIA9 Reveals Novel Insights into the Cell Cycle Roles of SIK2 in Ovarian Cancer Cells

Monika Raab, Marcel Rak, Roberta Tesch, Khayal Gasimli, Sven Becker, Stefan Knapp, Klaus Strebhardt, Mourad Sanhaji

Summary: The study found that MRIA9 enhances the efficacy of paclitaxel in eliminating ovarian cancer cells and inhibits the activity of SIK2, leading to abnormal mitosis. Additionally, MRIA9 increases sensitivity to paclitaxel, suggesting selective targeting of SIK2 in ovarian cancer as a potential therapeutic strategy for overcoming paclitaxel resistance.

CANCERS (2021)

Article Biochemistry & Molecular Biology

A dimerization-dependent mechanism regulates enzymatic activation and nuclear entry of PLK1

Monika Raab, Yves Matthess, Christopher A. Raab, Niklas Gutfreund, Volker Doetsch, Sven Becker, Mourad Sanhaji, Klaus Strebhardt

Summary: PLK1 activation during the G2 phase is controlled by dimerization supported by Bora and dissociation triggered by Aurora-A phosphorylation, allowing timely entry into mitosis. Interfering with this dimer/monomer switch affects PLK1's nuclear shuttling and localization during the G2-M transition, suggesting potential for novel PLK1 inhibitors.

ONCOGENE (2022)

Review Oncology

Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer

Maximilian Fleischmann, Georgios Chatzikonstantinou, Emmanouil Fokas, Jorn Wichmann, Hans Christiansen, Klaus Strebhardt, Claus Roedel, Nikolaos Tselis, Franz Roedel

Summary: Despite advancements in screening and vaccination programs, uterine cervical cancer remains a leading cause of cancer-related mortality in women worldwide. New therapeutic approaches have not significantly improved treatment response and prognosis, highlighting the urgent need for robust molecular markers to predict therapy response and clinical outcome.

CANCERS (2021)

Article Biochemistry & Molecular Biology

Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification

Khayal Gasimli, Monika Raab, Morva Tahmasbi Rad, Elisabeth Kurunci-Csacsko, Sven Becker, Klaus Strebhardt, Mourad Sanhaji

Summary: This study found that amplification of KRAS may be the underlying cause of PARPi resistance in BRCA2-deficient high-grade serous ovarian cancer (HGSOC). Inhibition of PLK1 has shown to restore sensitivity to PARPi in KRAS-amplified HGSOC and enhance the cellular apoptotic response to carboplatin-based chemotherapy. These findings shed new light on the role of PLK1 in reversing PARPi resistance and offer a potential therapeutic strategy for ovarian cancer patients.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Oncology

Prognostic Impact of Caspase-8, CDK9 and Phospho-CDK9 (Thr 186) Expression in Patients with Uterine Cervical Cancer Treated with Definitive Chemoradiation and Brachytherapy

Maximilian Fleischmann, Ranadip Mandal, Izabela Kostova, Monika Raab, Mourad Sanhaji, Stephanie Hehlgans, Markus Diefenhardt, Claus Roedel, Emmanouil Fokas, Klaus Strebhardt, Franz Roedel

Summary: Elevated levels of caspase-8 and CDK9 are associated with improved outcomes in cervical cancer patients treated with primary platinum-based chemoradiation, while higher levels of phosphorylated CDK9 predict worse survival. Biomarker research can help improve treatment strategies for cervical cancer patients.

CANCERS (2022)

Correction Biochemistry & Molecular Biology

A dimerization-dependent mechanism regulates enzymatic activation and nuclear entry of PLK1 (vol 41, pg 372, 2022)

Monika Raab, Yves Matthess, Christopher A. Raab, Niklas Gutfreund, Volker Doetsch, Sven Becker, Mourad Sanhaji, Klaus Strebhardt

ONCOGENE (2023)

暂无数据